Diaxonhit Aktie
| 24,20EUR | 0,50EUR | 2,11% |
WKN DE: A2DVTN / ISIN: FR0013240934
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 169 | 286 | 0 | 300 | 360 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1,09 | 0,53 | 0,00 | 0,52 | 0,47 |
Bilanz (in Mio. EUR) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 173 | 148 | 143 | 89 | 0 |
| Summe Anlagevermögen | 36 | 182 | 172 | 168 | 0 |
| Summe Aktiva | 209 | 330 | 316 | 257 | 0 |
Bilanz (in Mio. EUR) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 49 | 158 | 141 | 78 | 0 |
| Summe Eigenkapital | 160 | 172 | 175 | 178 | 184 |
| Summe Passiva | 209 | 330 | 316 | 257 | 0 |
Adresse
| ZA de Courtaboeuf, 91953 Les Ulis | |
| Telefon | +33 (1) 69-79-64-80 |
| Internet | http://www.eurobio-scientific.fr |
Management
|
Cathie Marsais
Chief Operating Officer & Deputy CEO |
|
Denis Fortier
Chairman & Chief Executive Officer |
|
Grégoire Sentilhes
Director |
|
Hanneke Merkens
Chief Marketing & Communication Officer |
|
Hervé Duchesne de Lamotte
Director & Deputy Chief Executive Officer |
|
Jacques Martin
Vice President-Marketing |
|
Jean-Michel Carle Grandmougin
Director & Deputy Chief Executive Officer |
|
Maarten Penning
Chief Technology Officer |
|
Michel Picot
Independent Director |
|
Olivier Bosc
CFO & Head-Information Technology |
|
Patrick de Roquemaurel
Independent Director |
|
Thomas Moreaux
Chief Human Resources Officer |